You are here

Protein Sequencing Tools for Biological Therapeutics

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42GM103362-03
Agency Tracking Number: R42GM103362
Amount: $988,836.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 400
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-07-01
Award End Date (Contract End Date): 2017-12-31
Small Business Information
1622 SAN CARLOS AVE, SUITE C
San Carlos, CA 94070-2060
United States
DUNS: 967100921
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID FENYO
 (917) 754-6066
 david@fenyolab.org
Business Contact
 DAVID FENYO
Phone: (917) 754-6066
Email: david@fenyolab.org
Research Institution
 NEW YORK UNIVERSITY SCHOOL OF MEDICINE
 
One Park Avenue 6th Floor
NEW YORK, NY 10016-5802
United States

 Nonprofit College or University
Abstract

DESCRIPTION provided by applicant Mass spectrometry has become a method of choice for identifying and characterizing small quantities of proteins in complex mixtures However the ability to perform the identification in a high throughput fashion has depended on the availability
of high quality protein sequence databases This means that proteins from organisms with unsequenced or poorly sequenced genomes e g peptide toxins and proteins that modify their primary sequences rapidly in response to the environment e g antibodies have been excluded from high throughput analysis Widespread availability of Next Generation Sequencing NGS has not alleviated this problem but rather NGS has led to a proliferation of lower quality uncurated protein sequence databases including personalized databases cancer databases and databases with uncertain assembly The traditional division between database search proteomics and de novo peptide sequencing no longer holds many of the most interesting biological questions are now best addressed by data analysis that combines the best of both techniques In this Phase II STTR project we propose to develop two commercial software products for sequencing biologically interesting peptides and proteins regardless of the quality of sequence databases One product will be aimed at the peptide level with applications to variable regions of circulating antibodies peptide toxins and human leukocyte antigens The other product will be aimed at the protein level with applications to end to end sequencing of purified proteins especially therapeutic monoclonal antibodies This system will include the peptide level sequencer as a component as well as tools for assembly of the peptides into the full sequence and for visualization and manual validation The proposed project has the potential for great impact on human health in areas such as vaccine development therapeutic antibody development and cancer immunotherapies PUBLIC HEALTH RELEVANCE We propose to develop commercial software products for sequencing biologically important peptides and proteins regardless of the existence or quality of available protein sequence databases The proposed project has the potential for great impact on human health in areas such as vaccine development therapeutic antibody development and cancer immunotherapies

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government